Trials / Completed
CompletedNCT04342572
Intra-arterial Chemotherapy for Retinoblastoma
Intra-arterial Chemotherapy for Retinoblastoma (IAC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 4 Months
- Healthy volunteers
- Not accepted
Summary
Children with retinoblastoma who may benefit from intra-arterial chemotherapy will receive up to 3 doses of melphalan and will be assessed for feasibility, toxicity, and response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melphalan | -The drug is commerically available |
Timeline
- Start date
- 2020-08-11
- Primary completion
- 2023-01-04
- Completion
- 2025-03-21
- First posted
- 2020-04-13
- Last updated
- 2025-05-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04342572. Inclusion in this directory is not an endorsement.